FGFR3 and urinary bladder cancer: The superiority of this biomarker compared to others may stem from its design of combining genomic alteration, such as in FGFR3 gene, which subsequently encodes a tyrosine kinase receptor that can activate the often‐dysregulated Ras‐MAPK pathway in bladder cancer, with distinct DNA methylation patterns that can affect different processes, ranging from cell cycle arrest, transcription, apoptosis, and cell differentiations.34